• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床II期非精原细胞性生殖细胞睾丸肿瘤。原发性化疗的治疗结果。

Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy.

作者信息

Peckham M J, Hendry W F

出版信息

Br J Urol. 1985 Dec;57(6):763-8. doi: 10.1111/j.1464-410x.1985.tb07050.x.

DOI:10.1111/j.1464-410x.1985.tb07050.x
PMID:2417652
Abstract

Between 1977 and 1984, 92 patients with clinical Stage II non-seminomatous germ-cell testicular tumours were treated by primary chemotherapy, with surgery reserved for the excision of persisting masses. Eighty patients (87%) are alive and disease-free: 96% for Stages IIA and IIB and 74% for Stage IIC. Of 43 Stage IIA, B and C patients treated with bleomycin, etoposide and cisplatin (BEP), 40 (93%) are disease-free. For the whole group there was a significant difference between the outcome of treatment in patients with retroperitoneal masses greater than 8 cm in transverse diameter compared with those in whom masses were less than 8 cm, the disease-free rates being 54 and 97% respectively. Primary histology did not influence the outcome of treatment. However, whereas 51% of patients with teratocarcinoma had masses resected after chemotherapy, only 26% of embryonal carcinoma patients came to surgery. The results obtained in this series are as good as those obtained when lymph node dissection is employed as the initial form of treatment. The avoidance of surgery with preservation of ejaculatory function in 78% of Stage IIA and IIB patients argues in favour, of an initially non-surgical approach to management.

摘要

1977年至1984年间,92例临床II期非精原细胞性生殖细胞睾丸肿瘤患者接受了一线化疗,手术仅用于切除残留肿块。80例患者(87%)存活且无疾病:IIA期和IIB期患者为96%,IIC期患者为74%。在43例接受博来霉素、依托泊苷和顺铂(BEP)治疗的IIA、B和C期患者中,40例(93%)无疾病。对于整个组而言,横径大于8 cm的腹膜后肿块患者与肿块小于8 cm的患者相比,治疗结果存在显著差异,无病生存率分别为54%和97%。原发组织学不影响治疗结果。然而,51%的畸胎癌患者在化疗后进行了肿块切除,而只有26%的胚胎癌患者接受了手术。该系列研究所得结果与采用淋巴结清扫作为初始治疗方式时的结果相当。在IIA期和IIB期患者中,78%的患者避免了手术并保留了射精功能,这支持了最初采用非手术治疗方法的观点。

相似文献

1
Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy.临床II期非精原细胞性生殖细胞睾丸肿瘤。原发性化疗的治疗结果。
Br J Urol. 1985 Dec;57(6):763-8. doi: 10.1111/j.1464-410x.1985.tb07050.x.
2
[Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].改良腹膜后淋巴结清扫术治疗睾丸非精原细胞性生殖细胞肿瘤的疗效
Ai Zheng. 2008 Dec;27(12):1302-6.
3
[Modified retroperitoneal lymphadenectomy in non-seminomatous stage I, IIa and IIb testicular tumors].[非精原细胞瘤 I 期、IIa 期和 IIb 期睾丸肿瘤的改良腹膜后淋巴结清扫术]
Urologe A. 1995 Nov;34(6):444-8.
4
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.基于预后不良生殖细胞肿瘤肿瘤标志物下降的个体化化疗(GETUG 13):一项3期多中心随机试验
Lancet Oncol. 2014 Dec;15(13):1442-1450. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.
5
[Urologic treatment of testicular germ cell cancer].睾丸生殖细胞癌的泌尿外科治疗
Arch Esp Urol. 2002 Oct;55(8):927-36.
6
Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis.基于顺铂的原发性标准化疗方案治疗临床II期睾丸非精原细胞瘤的疗效评估。
Br J Urol. 1997 Feb;79(2):258-62. doi: 10.1046/j.1464-410x.1997.26119.x.
7
The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.博来霉素对低危生殖细胞肿瘤化疗后腹膜后淋巴结清扫术的腹膜后组织学的影响。
J Urol. 2015 Feb;193(2):507-12. doi: 10.1016/j.juro.2014.09.090. Epub 2014 Sep 22.
8
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.德国睾丸癌研究组进行的AUO试验AH 01/94:一项随机III期试验,比较腹膜后淋巴结清扫术与博来霉素、依托泊苷联合顺铂化疗一个疗程在临床I期非精原性睾丸生殖细胞肿瘤辅助治疗中的效果。
J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Epub 2008 May 5.
9
Management of patients with clinical stage I or II nonseminomatous germ cell tumors of the testis. Evolving therapeutic options.睾丸临床I期或II期非精原细胞性生殖细胞肿瘤患者的管理。不断发展的治疗选择。
Arch Surg. 1987 Dec;122(12):1443-5. doi: 10.1001/archsurg.1987.01400240091016.
10
[Delayed retroperitoneal lymph node excision in treatment of advanced non-seminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor].[晚期非精原细胞性生殖细胞肿瘤的延迟性腹膜后淋巴结切除术。I. 标志物转换型肿瘤的术中发现]
Urologe A. 1993 May;32(3):189-93.

引用本文的文献

1
A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours.对接受非精原细胞瘤性生殖细胞肿瘤治疗的个体在化疗后腹膜后淋巴结清扫术中预测坏死或纤维化的临床病理特征的荟萃分析。
Front Oncol. 2022 Aug 17;12:931509. doi: 10.3389/fonc.2022.931509. eCollection 2022.
2
[Reduced morbidity in resection of residual tumors after chemotherapy for seminoma].[化疗后精原细胞瘤残留肿瘤切除的发病率降低]
Urologe A. 2015 Oct;54(10):1402-6. doi: 10.1007/s00120-014-3708-9.
3
Testicular germ cell tumors: pathogenesis, diagnosis and treatment.
睾丸生殖细胞肿瘤:发病机制、诊断与治疗。
Nat Rev Endocrinol. 2011 Jan;7(1):43-53. doi: 10.1038/nrendo.2010.196. Epub 2010 Nov 30.
4
Canadian consensus guidelines for the management of testicular germ cell cancer.加拿大睾丸生殖细胞癌管理共识指南
Can Urol Assoc J. 2010 Apr;4(2):e19-38. doi: 10.5489/cuaj.815.
5
Stage II nonseminomatous germ-cell testicular tumors--the Indiana experience and risk-benefit analysis.II期非精原细胞性生殖细胞睾丸肿瘤——印第安纳州的经验及风险效益分析
World J Urol. 1994;12(3):143-6; discussion 147. doi: 10.1007/BF00192274.
6
Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis.
World J Urol. 1994;12(3):113-9. doi: 10.1007/BF00192265.
7
Primary chemotherapy in the management of low stage (IIA and IIB) non-seminomatous germ cell testicular tumours.
Int Urol Nephrol. 1992;24(3):299-304. doi: 10.1007/BF02549539.